Our top pick for
Smith & Nephew plc is a medical devices business based in the US. Smith-and-Nephew shares (SNN) are listed on the NYSE and all prices are listed in US Dollars. Smith-and-Nephew employs 17,914 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$33.87 - $45.54|
|50-day moving average||$38.58|
|200-day moving average||$40.29|
|Wall St. target price||$49.50|
|Dividend yield||$0.375 (0.91%)|
|Earnings per share (TTM)||$1.02|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Smith-and-Nephew stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Smith-and-Nephew's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Smith-and-Nephew's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Smith-and-Nephew shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Smith-and-Nephew's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8725. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Smith-and-Nephew's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Smith-and-Nephew's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $883 million.
The EBITDA is a measure of a Smith-and-Nephew's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$4.6 billion|
|Operating margin TTM||9.5%|
|Gross profit TTM||$3.2 billion|
|Return on assets TTM||2.67%|
|Return on equity TTM||8.6%|
|Market capitalisation||$18.1 billion|
TTM: trailing 12 months
There are currently 1.1 million Smith-and-Nephew shares held short by investors – that's known as Smith-and-Nephew's "short interest". This figure is 24.4% down from 1.5 million last month.
There are a few different ways that this level of interest in shorting Smith-and-Nephew shares can be evaluated.
Smith-and-Nephew's "short interest ratio" (SIR) is the quantity of Smith-and-Nephew shares currently shorted divided by the average quantity of Smith-and-Nephew shares traded daily (recently around 448450.19920319). Smith-and-Nephew's SIR currently stands at 2.51. In other words for every 100,000 Smith-and-Nephew shares traded daily on the market, roughly 2510 shares are currently held short.
However Smith-and-Nephew's short interest can also be evaluated against the total number of Smith-and-Nephew shares, or, against the total number of tradable Smith-and-Nephew shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Smith-and-Nephew's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Smith-and-Nephew shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Smith-and-Nephew shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Smith-and-Nephew.
Find out more about how you can short Smith-and-Nephew stock.
Dividend payout ratio: 1.66% of net profits
Recently Smith-and-Nephew has paid out, on average, around 1.66% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.82% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Smith-and-Nephew shareholders could enjoy a 1.82% return on their shares, in the form of dividend payments. In Smith-and-Nephew's case, that would currently equate to about $0.375 per share.
While Smith-and-Nephew's payout ratio might seem low, this can signify that Smith-and-Nephew is investing more in its future growth.
Smith-and-Nephew's most recent dividend payout was on 11 May 2021. The latest dividend was paid out to all shareholders who bought their shares by 4 April 2021 (the "ex-dividend date").
Smith-and-Nephew's shares were split on a 2499:1000 basis on 14 October 2014. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 2499 shares. This wouldn't directly have changed the overall worth of your Smith-and-Nephew shares – just the quantity. However, indirectly, the new 60% lower share price could have impacted the market appetite for Smith-and-Nephew shares which in turn could have impacted Smith-and-Nephew's share price.
Over the last 12 months, Smith-and-Nephew's shares have ranged in value from as little as $33.8735 up to $45.5399. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Smith-and-Nephew's is 0.3882. This would suggest that Smith-and-Nephew's shares are less volatile than average (for this exchange).
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.